References

Advice

Abbott Healthcare Products Limited (2008) Omacor summary of product characteristics [online; accessed 12 July 2013]

Amdipharm Mercury Company Limited (2012) Teromeg 1000 mg capsules summary of product characteristics [online; accessed 12 July 2013]

Berger GE, Proffitt TM, McConchie M et al. (2007) Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. The Journal of Clinical Psychiatry 68: 1867–75

Emsley R, Myburgh C, Oosthuizen P et al. (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. The American Journal of Psychiatry 159: 1596–8

Emsley R, Niehaus DJH, Koen L et al. (2006) The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophrenia Research 84: 112–20

Emsley R, Niehaus DJH, Oosthuizen PP et al. (2008) Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Research 161: 284–91

Fenton WS, Dickerson F, Boronow J et al. (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. The American Journal of Psychiatry 158: 2071–4

Freeman MP, Hibbeln JR, Wisner KL et al. (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. The Journal of Clinical Psychiatry 67: 1954–67

Fusar-Poli P, Berger G (2012) Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 32: 179–85 doi: 10.1097/JCP.0b013e318248b7bb

General Medical Council (2013) Prescribing guidance: prescribing unlicensed medicines [online; accessed 12 July 2013]

Health & Social Care Information Centre (2013) Prescription cost analysis - England, 2012 [online; accessed 12 July 2013]

Irving CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews Issue 3: CD001257 doi: 10.1002/14651858.CD001257.pub2

Leucht S, Kane JM, Etschel E et al. (2006) Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31: 2318–25 doi: 10.1038/sj.npp.1301147

Levine SZ, Rabinowitz J, Engel R et al. (2008) Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophrenia Research 98: 318–22

Manteghiy A, Shakeri MT, Koohestani L et al. (2008) Beneficial antipsychotic effects of omega-3 fatty acids add-on therapy for the pharmacological management of patients with schizophrenia. Iranian Journal of Psychiatry and Behavioral Sciences 2: 35–40

David Taylor (Editor), Carol Paton (Co-Editor), Shitij Kapur (Co-Editor) (2012) The Maudsley Prescribing Guidelines in Psychiatry, 11th Edition. Wiley-Blackwell

National Health Service England and Wales (2013) NHS electronic drug tariff [online; accessed 5 August 2013]

National Institute for Health and Clinical Excellence (2013) Psychosis and schizophrenia: recognition and management of psychosis and schizophrenia in children and young people. NICE clinical guideline 155

National Institute for Health and Clinical Excellence (2009) Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE clinical guideline 82

National Institute for Health and Clinical Excellence (2011) Aripiprazole for schizophrenia in people aged 15 to 17 years. NICE technology appraisal guidance 213

National Institute for Health and Clinical Excellence (2013) Omega-3 fatty acid supplements. Key therapeutic topic 4

Peet M, Brind J, Ramchand CN et al. (2001a, 2001b) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 49: 243–51

Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36: 7–18

Politi P, Rocchetti M, Emanuele E et al. (2013) Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders: a review of the current literature. Current Drug Discovery Technologies 10: 245–53 doi: 10.2174/1570163811310030007

Ross BM, Seguin J, Sieswerda LE (2007) Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids in Health and Disease 6: 21 doi: 10.1186/1476-511X-6-21

Seven Seas Ltd (2012) Maxepa summary of product characteristics [online; accessed 12 July 2013]